JAC Advance Access published online on March 7, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn076
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original research |
Activity of BAL 4815 against filamentous fungi
1 Servicio de Microbiología y Parasitología, Hospital Universitario de Valme, Carretera de Cádiz s/n, Sevilla, Spain 2 Hospital La Fe, Avda. Campanar 21, Valencia 46009, Spain 3 Hospital Puerta del Mar, Avda. Ana de Viya 21, Cádiz, 11009, Spain
Received 14 May 2007; returned 3 July 2007; revised 28 January 2008; accepted 1 February 2008
* Corresponding author. Tel: +34-955015480; Fax: +34-955015481; E-mail: cemarmar{at}gmail.com
Objectives: BAL 4815 is a new antifungal drug and it is the active component of the antifungal triazole BAL 8557 (the water-soluble precursor). We studied the in vitro fungistatic and fungicidal activities of BAL 4815 against 103 clinical isolates of filamentous fungi, including 51 isolates of Aspergillus spp. and 52 isolates of non-Aspergillus filamentous fungi.
Methods: We evaluated the in vitro activity of BAL 4815 against 51 isolates of Aspergillus spp., 20 isolates of dematiaceous fungi, 18 isolates of hyaline Hyphomycetes and 14 isolates of Zygomycetes. MICs were determined following the CLSI M38-A broth microdilution method, using RPMI 1640 medium buffered to pH 7.0 with MOPS. Microdilution plates were incubated at 35°C and read at 24 and 48 h (Mucorales were read at 24 h). Minimal fungicidal concentrations were also determined.
Results: For all isolates, geometric mean MICs, MIC50s, MIC90s and MIC ranges (mg/L) were: Aspergillus spp., 1.67, 2, 4 and 0.5–4; dematiaceous fungi, 1.62, 1, >8 and 0.03 to >8; hyaline Hyphomycetes, 2.41, 2, >8 and 0.03 to >8; and Zygomycetes, 6.81, 8, >8 and 0.03 to >8. Differences in susceptibility between genera were noted. Scedosporium prolificans, Fusarium spp., Mucor spp. and Rhizopus spp. (MIC90 > 8 mg/L) were less susceptible than Aspergillus spp. (MIC90 = 4 mg/L).
Conclusions: BAL 4815 has excellent in vitro activity against Aspergillus spp. and variable activity against other filamentous fungi.
Key Words: Aspergillus , triazoles , antifungals
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Schmitt-Hoffmann, B. Roos, J. Spickermann, M. Heep, E. Peterfai, D. J. Edwards, and K. Stoeckel Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557 Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4885 - 4890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Perkhofer, V. Lechner, and C. Lass-Florl In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1645 - 1647. [Abstract] [Full Text] [PDF]
|
|